ˈɛfɐlˌɪzjuːmˌæb bˈaɪndz tə ðə sˌiːdˈiː ɪlˈɛvən ˈeɪ sˈʌbjuːnˌɪt ʌv lˈɪmfəsˌaɪt fˈʌŋkʃənɐsˈoʊsɪˌeɪɾᵻd ˈæntɪdʒˌɛn wˈʌn ænd ˈækts æz ɐn ɪmjˈuːnəsˌʌpɹɛsənt baɪ ɪnhˈɪbɪɾɪŋ lˈɪmfəsˌaɪt ˌæktɪvˈeɪʃən ænd sˈɛl maɪɡɹˈeɪʃən ˌaʊɾəv blˈʌd vˈɛsəlz ˌɪntʊ tˈɪʃuːz.
Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues.